Spots Global Cancer Trial Database for An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Official Title: An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Study ID: NCT03460782

Conditions

Glioblastoma

Glioma of Brain

Interventions

Ipilimumab

Study Description

Brief Summary: IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.

Detailed Description: It is not yet known which protocols are a better treatment for glioblastoma or glioma. The ipilimumab extended-access program for patients who received previous chemotherapy and / or radiation therapy by protocol, before ((for non-operable cases) or after the operation. Monoclonal antibodies of CTLA-4, such as ipilimumab, may block tumor growth in different ways by targeting certain cells and activating the patient's immune system to fight the disease.